Social Anxiety Medication: Evidence-Based Review
medication can significantly ease social anxiety disorder (SAnD) symptoms, and a recent review of 66 trials confirms ssris’ effectiveness, making it a promising treatment option. The analysis, involving nearly 11,600 participants, revealed that SSRIs outperform placebos in mitigating SAnD. Monoamine oxidase inhibitors (MAOIs), RIMAs, and benzodiazepines also showed benefits. While some medications presented more side effects, the overall withdrawal rates remained low. Gabapentin and pregabalin offered clinical responses, too. News Directory 3 provides critical updates on mental health research. Further research will focus on individuals with co-occurring disorders for better social anxiety management. Discover what’s next in innovative treatments.
Medications ease Social Anxiety Disorder Symptoms
Updated June 06, 2025
For adults grappling with social anxiety disorder (SAnD), medication may offer relief. A review of 66 trials involving nearly 11,600 participants suggests that selective serotonin reuptake inhibitors (SSRIs) are more effective than placebos in minimizing SAnD symptoms. The analysis also found some benefit from monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase A (RIMAs), and benzodiazepines.
The review examined the effectiveness and tolerability of various medications for SAnD, also exploring factors that might predict how individuals respond to pharmacotherapy. The findings indicated that SSRIs were the only medication class effective in reducing relapse, based on moderate-quality evidence.
While some evidence suggested that more people taking SSRIs and SNRIs dropped out of studies due to side effects compared to those on placebos, the overall withdrawal rates remained low. Gabapentin and pregabalin, anticonvulsants, also demonstrated a clinical response, according to moderate-quality evidence.
Beyond SSRIs,the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine,the antipsychotic olanzapine,and the noradrenergic and specific serotonergic antidepressant (NaSSA) atomoxetine also showed promise in reducing sand symptom severity,though the evidence was generally of very low quality. SSRIs and RIMAs were found to reduce depression symptoms,while SSRIs also lessened functional disability across various life domains.
The review also noted positive responses to long-term treatment with SSRIs, MAOIs, and RIMAs, even though the quality of evidence varied from low to moderate.
What’s next
Future research should focus on evaluating SAnD treatments for individuals with co-occurring disorders, including substance use disorders. The review authors emphasized the need for trials that provide complete details on randomization and allocation concealment to strengthen the evidence base for effective SAnD treatments and social anxiety management.